European EMA Approves Piramal Imaging's Neuraceq, an Amyloid PET Diagnostic Agent for Alzheimer's Disease
Amyloid Visualization Clinical Data and Approval Background
The European Medicines Agency (EMA) has approved Neuraceq (active ingredient: flutemetamol 18F), a radiotracer that visualizes beta-amyloid neuron plaque density in the brains of patients with Alzheimer's disease and cognitive impairment. This approval is based on data from a Phase 3 trial (NCT01020838) that directly compared Neuraceq PET imaging results with post-mortem brain tissue biopsy (histopathology) results. Clinical analysis showed that Neuraceq has high diagnostic accuracy, with a sensitivity of 97.9% and a specificity of 88.9%, accurately identifying pathological changes. This provides a foundation for significantly increasing the early diagnosis rate of Alzheimer's disease in clinical practice based on objective biomarker validation.
Excellent Competitive Advantage and Positioning Based on Fluorine-18
Unlike existing PiB tracers that use carbon-11 (11C), Neuraceq is labeled with the fluorine-18 (18F) radioisotope, giving it a relatively long half-life of approximately 110 minutes. This overcomes the limitations of existing diagnostic agents, which were previously limited to use near cyclotron production facilities, and enables wider distribution and use. The main competing drugs in the market include Amyvid (active ingredient: flutemetamol 18F) from Eli Lilly and Vizamyl (active ingredient: flutemetamol 18F) from GE HealthCare. With its precise brain region-specific plaque distribution assessment function and excellent image quality, Neuraceq is clearly establishing itself as a differentiated diagnostic option in the European market.
Overcoming Reimbursement Barriers and Market Stimulation with the Launch of Therapeutic Agents
The healthcare systems in European countries have different reimbursement criteria for diagnostic radiopharmaceuticals, which may slow down the initial market entry. In addition, the high cost of PET equipment and the regional disparities in fluorine supply infrastructure are also cited as major obstacles to market expansion. However, the situation has changed rapidly with the recent approval of Eisai and Biogen's Leqembi (active ingredient: lecanemab) and Eli Lilly's Kisunla (active ingredient: donanemab), anti-amyloid monoclonal antibody therapeutic agents. As confirmation of amyloid deposition becomes a prerequisite for the prescription of therapeutic agents, the application of insurance reimbursement for diagnostic agents is also expected to expand rapidly in the future.
Business Value Proven Through Major M&A and Sales Forecast
The marketing rights for Neuraceq were acquired by Piramal Imaging in 2012 through the acquisition of a portfolio from Bayer, and in 2018, it was acquired by Alliance Medical for up to $200 million. In 2025, Lantheus Holdings (LNTH) acquired Life Molecular Imaging for a total of $750 million, including an upfront payment of $350 million and milestone payments of $400 million, re-demonstrating its commercial value. Neuraceq generated sales of $31 million in the fourth quarter of 2025 alone, and with the Alzheimer's diagnostic market expected to grow to approximately $9.94 billion in 2025, continued sales growth is expected.
The EMA approval of Neuraceq officially recognizes its high diagnostic performance, with a sensitivity of 97.9% and a specificity of 88.9%, as demonstrated in a post-mortem tissue biopsy comparative Phase 3 trial, thereby establishing a clinical standard for amyloid PET diagnostics. In the short term, in a three-way competitive landscape with Amyvid and Vizamyl, it is expected to aggressively expand its market share of radiopharmaceutical supply chains in Europe by leveraging its longer half-life for wider distribution. In the medium to long term, in conjunction with the essential co-diagnostic demand for amyloid-targeting Alzheimer's therapeutic agents such as Leqembi, it is expected to drive the growth of the Alzheimer's diagnostic market, which is approximately $9.94 billion in 2025. In particular, with Lantheus Holdings' acquisition of Life Molecular Imaging for $750 million in 2025, venture capital investment for the expansion of global AD diagnostic infrastructure and the development of new diagnostic pipelines is expected to be further activated.
Source: EMA (ema)